PMC8474378_01
Intergenic ALK fusion detected by DNA-based NGS and tumor response of the patient's right lung lesion during alectinib treatment. (A) Schematic diagram of the detected fusion. This variant was generated by the fusion of the intergenic region with exons 20 to 29 of ALK. (B) Baseline before alectinib treatment. (C) The tumor decreased considerably after 3 months of alectinib treatment. NGS, next-generation sequencing.
gr1.jpg
PMC8474378_01_gr1.jpg
fig1
American Pathologists-certified laboratory). A novel intergenic ALK fusion was detected (Fig. 1A). The patient then achieved partial response within 3 months (Fig. 1B and C), and the progression-free survival (PFS) exceeded 6 months by the time of submission.